Evidence map›Paper›PMID 28082400›Full record

ArticleCancer research2017

ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Tomasz B Owczarek, Takashi Kobayashi, Ricardo Ramirez, Lijie Rong, Anna M Puzio-Kuter, Gopa Iyer, Min Yuen Teo, Francisco Sánchez-Vega, Jingqiang Wang, Nikolaus Schultz and 4 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Molecular therapy. Oncology · 2024
    Article
  3. ITGB3BP is a potential biomarker associated with poor prognosis of glioma.Journal of cellular and molecular medicine · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. The nucleolus, an ally, and an enemy of cancer cells.Histochemistry and cell biology · 2018
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Tomasz B OwczarekDepartment of Medicine, Columbia University Medical Center, New York, New York.
Takashi KobayashiDepartment of Urology, Columbia University Medical Center, New York, New York.
Ricardo RamirezDepartment of Human Oncology and Pathogenesis, Memorial Sloan-Kettering Cancer Center, New York, New York.
Lijie RongDepartment of Medicine, Columbia University Medical Center, New York, New York.
Anna M Puzio-KuterDepartment of Urology, Columbia University Medical Center, New York, New York.
Gopa IyerDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Min Yuen TeoDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Francisco Sánchez-VegaDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Jingqiang WangDepartment of Urology, Columbia University Medical Center, New York, New York.
Nikolaus SchultzDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Tian ZhengDepartment of Statistics, Columbia University, New York, New York.
David B SolitDepartment of Human Oncology and Pathogenesis, Memorial Sloan-Kettering Cancer Center, New York, New York.
Hikmat A Al-AhmadieDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Cory Abate-ShenDepartment of Medicine, Columbia University Medical Center, New York, New York. cabateshen@columbia.edu.
Memorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USColumbia University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Investigating the cell of origin for bladder cancerR01CA193442 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2019
$2.4M
Defining the temporal sequence of PI3K pathway mutations in bladder cancerR01CA182587 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2014 to 2018
$1.8M
Analysis of drug response in organoids and mouse modelsR01CA196662 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY, SHEN, MICHAEL M. · 2016 to 2018
$1.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA182587NCI NIH HHS R01 CA193442NCI NIH HHS R01 CA196662
6 · The paper itself

Abstract

Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14

Indexed as

AdultAgedAged, 80 and overAnimalsCell Line, TumorCisplatinDNA DamageDrug Resistance, NeoplasmFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedNeoplasm InvasivenessNuclear ProteinsCisplatinITGB3BP protein, humanNuclear ProteinsTumor Suppressor Protein p14ARFTumor Suppressor Protein p53

Identifiers

PMID28082400
PMCPMC5313321
OpenAlexW2579848668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.